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 STUDY PROTOCOL Open Access
Self-monitoring of Blood Glucose in Non-
Insulin Treated Type 2 Diabetes (The SMBG
Study): study protocol for a randomised
controlled trial
Sharon Parsons1*† , Stephen Luzio1†, Stephen Bain1, John Harvey2, Jillian McKenna1, Atir Khan3, Sam Rice4,
Alan Watkins5 and David R. Owens1
Abstract
Background: The benefit of Self-monitoring of Blood Glucose (SMBG) in people with non-insulin treated type 2
diabetes remains unclear with inconsistent evidence from randomised controlled trials fuelling the continued
debate. Lack of a consistent finding has been attributed to variations in study population and design, including the
SMBG intervention. There is a growing consensus that structured SMBG, whereby the person with diabetes and
health care provider are educated to detect patterns of glycaemic abnormality and take appropriate action
according to the blood glucose profiles, can prove beneficial in terms of lowering HbA1c and improving overall
well-being. Despite this, many national health agencies continue to issue guidelines restricting the use of SMBG in
non-insulin treated type 2 diabetes.
Methods: The SMBG Study is a 12 month, multi-centre, randomised controlled trial in people with type 2 diabetes
not on insulin therapy who have poor glycaemic control (HbA1c≥58 mmol/mol / 7.5%). The participants will be
randomised into three comparative groups: Group 1 will act as a control group and receive their usual diabetes care;
Group 2 will undertake structured SMBG with clinical review every 3 months; Group 3 will undertake structured SMBG
with additional monthly telecare support from a trained study nurse. A total of 450 participants will be recruited from
16 primary and secondary care sites across Wales and England. The primary outcome measure will be HbA1c at
12 months with secondary measures to include weight, BMI, total cholesterol and HbA1c levels at 3, 6, 9 and
12 months. Participant well-being and attitude towards SMBG will be monitored throughout the course of the study.
Recruitment began in December 2012 with the last participant visit due in September 2016.
Discussion: This study will attempt to answer the question of whether structured SMBG provides any benefits to
people with poorly controlled type 2 diabetes who are not being treated with insulin. The data will also clarify whether
the telecare support provides additional value. The overall acceptability of SMBG as a tool for self-management will be
assessed.
Trial registration: UKCRN 12038 (Registered March 2012).
ISRCTN21390608 (Retrospectively registered 15th May 2014).
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Background
Self-monitoring of blood glucose (SMBG) is recom-
mended as a core element of self-management of dia-
betes when used appropriately following suitable
training [1, 2]. In persons requiring insulin therapy, the
information gained from SMBG can be used to adjust
lifestyle (nutrition and physical activity) and insulin
doses to optimise glycaemic control. However, the bene-
fit of SMBG in insulin naïve type 2 diabetes has not been
a consistent finding in the limited number of rando-
mised control trials (RCTs) published to date [3–12].
Consequently, NICE have recently issued guidelines [13]
similar to the US, Canada and Australia [14], recom-
mending limiting the use of SMBG in people with type 2
diabetes. However, current recommendations make
allowances where there is evidence of hypoglycaemic
episodes, the person is on oral medication that may
increase their risk of hypoglycaemia while driving or op-
erating machinery, during pregnancy, or when planning
to become pregnant. If adults with type 2 diabetes are
self-monitoring their blood glucose levels, NICE now
recommends a structured assessment should be carried
out at least annually.
The studies conducted on SMBG have varied in terms
of their methodology, populations and intervention
(format of SMBG). However, ‘structured SMBG’, in-
volving regular ‘paired blood glucose testing’ (pre and
post meal) to identify patterns of glycaemic control
along with education to interpret the results and ac-
tion taken to correct any abnormalities, has consist-
ently demonstrated clear benefits with improved
HbA1c and well-being [9, 14]. This approach is now
generally recommended as the optimum method for
blood glucose self- monitoring [1]. Clinical practice
suggests that many with type 2 diabetes perform
SMBG but do not act on the results thus underutilis-
ing its potential benefit in terms of necessary adjust-
ment of lifestyle and/or dose of oral hypoglycaemic
agents. Often, people with type 2 diabetes have not
had the necessary education or training to adjust their
lifestyle or oral medication even if they are aware that
their blood glucose results are abnormal [15].
In 2014/15, NHS expenditure on blood glucose moni-
toring agents and devices in England was £175.2 million.
This represents an increase of 23% since 2005/06 ac-
counting for just over 20% of the total cost of diabetes
treatments in England that year [16]. Despite the contin-
ued year on year rise in expenditure, HbA1c levels in
people with type 2 diabetes have remained static with
only approximately 66% reaching the NICE recom-
mended target of 58 mmol/mol (≤7.5%) [17]. As a con-
sequence the debate continues regarding the value of
SMBG in people with type 2 diabetes who are not on in-
sulin therapy [18–22].
Methods and study design
Aim
To demonstrate that a proactive, nurse-led service,
using structured SMBG, can enable poorly controlled
(HbA1c ≥58 mmol/mol / 7.5%) people with type 2 dia-
betes to better manage their diabetes. This is a rando-
mised clinical trial comparing the use of structured
SMBG when used alone, or with additional telecare
(additional telephone support by trained nurses who
will have the participants’ SMBG results available via
an electronic upload system) versus no SMBG in people
with type 2 diabetes not on insulin therapy which will
serve as the control group. Throughout the trial, the
well-being and satisfaction of participants will also be
evaluated.
This study aims to determine if HbA1c is significantly
improved at 12 months in participants who receive
SMBG compared to the control group and also to deter-
mine which of the two SMBG regimens has the greater
effect on reducing HbA1c.
Study design
The study is an open, multi-centre, randomized controlled
trial (RCT). Participants are involved for 12 months fol-
lowing randomisation to (1) a control group with no
SMBG monitoring, (2) structured SMBG alone and (3)
structured SMBG with telecare, as illustrated in the Study
Design Flow Chart (Fig. 1).
Setting and site selection
The study is being conducted at primary and secondary
care sites across Wales and England. Larger primary care
(GP) practices in Wales, defined as those with a practice
population greater than 9000, with over 500 people on
their Diabetes Disease Register of whom 20% or more
had sub-optimal blood glucose control according to
Quality and Outcomes Framework (QoF) data, were ini-
tially approached to take part in the study as recruiting
sites. Smaller, research active practices were also invited
to participate. Diabetologists working in secondary care
across Wales were invited to be involved by working in
partnership with GP practices i.e. Patient Identification
Centres. In addition, two sites in England, one in pri-
mary care and the other in secondary care, expressed an
interest in taking part and were accepted, making a total
of 16 centres (nine primary care sites and seven secondary
care sites).
Participants
Adults with established type 2 diabetes (>1 year duration)
not receiving insulin therapy will be invited to take part in
the study. Those recruited will meet the following inclu-
sion/exclusion criteria:
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Inclusion criteria
 Type 2 diabetes mellitus patients with a duration of
diabetes >1 year;
 Age ≥18<80 years;
 HbA1c ≥58 to ≤119 mmol/mol (≥7.5% to ≤13%);
 Willing and able to provide informed consent;
 Access to a telephone;
 Able to conduct blood glucose measurements.
Exclusion criteria
 Diabetes other than type 2 diabetes or type 2
diabetes treated with insulin;
 Pregnancy;
 Gestational diabetes mellitus;
 Severe chronic hepatic disease;
 Where using SMBG is part of their routine clinical
care;
 Participation in any investigational drug trial within
1 month prior to Visit 1;
 Mental condition rendering the participant unable
to understand the nature, scope and possible
consequences of the study;
 End-stage renal disease (existing or planned dialysis
or transplantation) or creatinine >150 umol/L;
 Blindness or severe loss of vision in both eyes.
Written informed consent will be given by the partici-
pant before any study activities take place. People with
type 2 diabetes eligible to take part in the study will
receive an invitation letter from their GP or hospital
consultant, along with a Participant Information Leaflet
and be given an oral explanation about the study from
a research professional (usually a research nurse).
Diabetes education
Following recruitment to the study all participants will
be asked to complete the Audit of Diabetes Knowledge
(ADKnowl) questionnaire to record their level of dia-
betes knowledge. Provision will be made to address any
educational gaps through the use of standardised dia-
betes education materials. All participants will be given a
copy of the Diabetes UK booklet on type 2 diabetes
[23–25] that they will keep throughout the study dur-
ation to use for their personal reference. Those in the
SMBG study arms (groups 2 and 3) will also be able to
refer to this booklet at clinic visits when care planning
with their study nurse.
Randomisation
Following acceptance into the study, participants will be
randomised into one of three treatment groups. The
randomisation procedure uses study site and previous
experience with SMBG (Yes/No) as stratifying factors,
and aims to allocate approximately equal numbers of
participants in the three groups overall, by site and by
previous experience. Randomisation will be performed
remotely by the Swansea Trials Unit (formerly West
Fig. 1 Study Design Flow Chart
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Wales Organisation for Rigorous Trials in Health and
social care (WWORTH)). Randomisation will be via
email using a central database.
Study visits
The study will involve six visits for those randomised to
the control group and an additional seventh visit for
those randomised to one of the SMBG groups to deliver
the SMBG training.
Visit 1 (Consent and screening visit)
At this visit and prior to any participant related activity,
written informed consent is provided by the participant.
Demographic data (such as sex, age, employment status)
will be recorded and participants will be screened against
the study inclusion/exclusion criteria. A blood sample will
be taken to ascertain whether the HbA1c level is within
the inclusion criteria. Following the visit all participants
will be contacted to notify them of the outcome of the
screening visit and those who meet the inclusion/exclu-
sion criteria will be invited back for visit 2.
Visit 2 (Baseline and randomisation visit)
At visit two participants will be randomised into one of
the three treatment groups. Participants will also be asked
to complete the ADKnowl questionnaire [26] to record
their current level of diabetes education. Standardised dia-
betes information (DUK Booklet [23–25]) will be given to
all participants to take away with them. Baseline data will
include collection of clinical data (e.g. height, weight, waist
circumference), details of current treatment, blood sample
for measurement of HbA1c and total cholesterol and par-
ticipant reported outcomes (ADDQoL, EQ-5D & PHQ-9
questionnaires) [27–29]. For the SMBG groups there will
also be a questionnaire assessing their attitude to SMBG.
Participants in all groups will be provided with a partici-
pant diary to record any significant events, change of
medication and contact with any health care professionals.
Visit 2a (SMBG groups only)
Participants randomised to the SMBG groups will attend
an individual training session with their study nurse on
blood glucose monitoring teaching them how to monitor
their blood glucose levels using the Accu-Chek Aviva
meter. Participants will also have the option of using the
Accu-Chek 360° Diabetes Management System and
Accu-Chek 360° View Paper Tool (Roche Diagnostics
GmbH, Mannheim, Germany). They will be taught blood
glucose pattern recognition and how to use the algorithm
supplied to self-adjust their lifestyle and/or treatment.
Visits 3–6 (3, 6, 9 and 12 months after visit 2)
During these visits the study nurse will carry out a re-
view of the participant similar to Visit 2. Procedures will
include collection of clinical data, details of current
treatment, blood sample for measurement of HbA1c and
total cholesterol, patient reported outcomes (EQ-5D &
PHQ-9) and review of participant diaries. Participants
will be asked to complete the ADDQoL questionnaire at
visits 4 and 6 (6 and 12 month follow up visits) and the
ADKnowl questionnaire at visit 6 (12 month follow up
visit). For those in the SMBG groups, the study nurse
will review the blood glucose readings and discuss and
agree a care plan for the next 3 months at each visit.
Participant diaries will be collected at the final visit.
The results from the study venous blood samples
taken will not be fed back to the participant, the study
nurse or any member of the participant’s health care
team in order to keep the primary outcome measure
(HbA1c) blinded across all treatment groups.
The intervention
As the study nurses will vary according to their knowledge
and expertise, all will attend a standardised training
programme delivered by the study team in addition to
completing online training covering the safe use of non-
insulin therapies in type 2 diabetes. The standardised
training programme will cover the correct technique for
self-monitoring blood glucose, use of the Accu-Chek 360°
View Tool and Accu-Chek 360° Diabetes Management
System, glycaemic pattern recognition and use of the study
specific participant and clinical algorithms. Refresher
training will be provided approximately every 4 months as
part of the study update meetings.
Throughout the study, participants in the control group
(Group 1), will receive routine care with the participant
able to contact their diabetes team or GP as they would
normally. Group 1 participants will not be provided with a
blood glucose meter and training on SMBG will not be
given. Glycaemic management will be by their usual health
care provider as part of routine clinical care.
Participants in the SMBG alone (Group 2) and SMBG
with telecare (Group 3) groups will be supplied with a
blood glucose meter and instructed how to take blood
glucose readings correctly. They will be taught blood
glucose pattern recognition using the Accu-Chek 360°
View Tool and will be offered the Accu-Chek 360° Dia-
betes Management System software to use at home if
they wish. Participants in the SMBG groups will be able
to understand their results and will have the ability to
adjust their lifestyle and/or medication based on SMBG
targets using an algorithm. Actions taken in response to
the blood glucose monitoring will be recorded. At each
study visit glycaemic management will be based on
SMBG results alone and refresher training will be given
on using the blood glucose meter correctly, understanding
SMBG profiles and following the algorithm. Additionally
the blood glucose meter will be calibrated.
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In addition to the education and support given to the
Group 2 participants (SMBG Alone), Group 3 partici-
pants (SMBG with Telecare) will be in regular contact
with their study nurse. Between the 3 monthly study
visits the participants will verbally report or upload their
SMBG results to the database (if using the software) for
the nurse to review on a monthly basis. Each month, the
study nurse will contact the participant by phone and re-
view the blood glucose readings, discussing any trends
of glycaemic abnormalities. A care plan is then devised
and agreed with the participant for the coming month.
Initiation and adjustment of therapy will be based on
the consensus statement from the ADA/EASD [30]. The
aim of treatment will be to obtain HbA1c 53 mmol/mol
(<7%) and fasting glucose <6.0 mmol/L and 2 h post-
prandial glucose <10 mmol/L. Initiation of insulin will
be considered if HbA1c is 69 mmol/mol (>8.5%), how-
ever, once a participant starts on insulin they will no
longer participate in the study.
Blood glucose measurements will be taken on two
days of every week during the study by all the partici-
pants in both SMBG groups (groups 2 & 3) which will
include a weekday and a day at the weekend. Blood glu-
cose will be measured fasting and 2 h after breakfast,
and pre and 2 h post the evening meal. In addition, in
the week prior to clinic attendance (study visit) partici-
pants will perform a 7 point blood glucose profile (pre
and 2 h following major meals, and bedtime) on three
days. At the clinic visits the meters will be downloaded
and calibrated.
Efficacy measures
The primary efficacy measure will be HbA1c at 12 months.
Secondary efficacy measures will include HbA1c at 3, 6
and 9 months; Total cholesterol at 3, 6, 9 and 12 months;
Weight; BMI; Waist circumference; Hypoglycaemia (symp-
tomatic/confirmed/nocturnal/severe - requiring third party
involvement); Hyperglycaemic events; Time to insulin treat-
ment; medication use; Health-related utility (EQ-5D),
disease-specific quality of life (ADDQoL), depression score
(PHQ-9) and use of health care resources; Percentage of
persons achieving target of HbA1c ≤ 53 mmol/mol (≤7%);
Time to reach HbA1c target; Acceptability of SMBG (mea-
sured by SMBG8/SMBG14 questionnaire).
Safety evaluations and data monitoring
The Data Monitoring Committee (DMC) will monitor
the overall conduct of the trial, safeguarding the inter-
ests of the trial participants and assessing the safety and
efficacy of the intervention. The HbA1c results reported
weekly by the accredited central laboratory will be moni-
tored by a sub-committee of the DMC to ensure any
participant in the control group whose HbA1c level de-
teriorates by more than 15% over a 6 month period or
exceeds 119 mmol/mol (13%) is flagged to their GP via
their local study site. The actual result will not be re-
ported to the local study team or any member of the
participant’s health care team until the participant has
completed the study.
Sample analysis
All samples will be analysed in a central accredited
diabetes laboratory, the Diabetes Research Unit Cymru
laboratory based at Swansea University. HbA1c will be
measured using both the Diabetes Control and Complica-
tions Trial (DCCT) aligned method and the International
Federation of Clinical Chemistry and Laboratory Medicine
(IFCC) standardised values [31].
Statistical analysis plan
The study will be analysed on a comparative basis. All
significance tests will be two tailed and carried out at
the 5% level. All available data from withdrawn subjects
will be included in the analysis up to the time of with-
drawal where possible. All statistical hypothesis tests will
be performed at a 5% significance level.
The primary objective of the trial will involve the ana-
lysis of HbA1c values at 12 months. These values will be
checked for Normality, applying suitable transformations
as necessary. The values will then be analysed using a
general linear model with baseline values and a nested
set of group identifiers included as explanatory covari-
ates and factors. The efficacy of the intervention will be
assessed by appropriate hypothesis tests on parameters
for group identifiers, with suitable allowance for multiple
comparisons.
Variables associated with secondary efficacy measures
will be summarised and analysed using the approach
outlined above for the primary measure, with linear
models used for continuous outcomes and binary logistic
regression models used for binary outcomes.
Sample size
Initial sample size considerations were based on previ-
ous data in which the response within each subject
group was normally distributed with standard deviation
of 13 mmol/mol HbA1c (1.2%). If the true difference in
the experimental and control means is 0.3%, (3 mmol/
mol) (corresponding to an effect size of 0.25), we will
need to study 378 experimental subjects and 189 control
subjects to be able to reject the null hypothesis that the
population means of the experimental and control
groups are equal with probability (power) 0.8. The Type
I error probability associated with this test of this null
hypothesis is 0.05. In summary, allowing for up to ap-
proximately 33% drop-out (to include participants who
convert to insulin), a total of 850 participants are re-
quired (n = 284 per treatment group).
Parsons et al. BMC Endocrine Disorders  (2017) 17:4 Page 5 of 7
Following the recruitment of the first participants, al-
though no formal interim analysis was proposed or under-
taken, initial routine checks on data quality following
recruitment of the first wave of participants provided an
opportunity to review some of the assumptions underpin-
ning our original sample size calculations. It became obvi-
ous that if we remained with our initial inclusion criteria
of HbA1c (≥64 mmol/mol/ ≥8% to ≤97 mmol/mol/ ≤11%)
a large number of participants would be missed. We
therefore modified the criteria to ≥58 mmol/mol (7.5%)
to ≤119 mmol/mol (13%). The review also showed that,
first, the drop-out rate was likely to be smaller than origin-
ally expected and, second, that our original estimate of an
effect size of 0.25 seemed to be conservative, with evi-
dence to support increasing this to 0.333.
With all other elements in sample size considerations
held fixed, the combined effect of these changes means
that a total sample size of between n = 398 and n = 424
would be sufficient to achieve the study aims. Our re-
vised target is now 450 (n = 150 per treatment group),
which is higher and enables us to be confident that the
proposed sample size will prove to have sufficient statis-
tical power for our planned analyses and reports.
Discussion
The debate still continues regarding the effectiveness
and value for money of SMBG in people with type 2 dia-
betes who are not receiving treatment with insulin. A
number of diabetes disease management programmes
have been developed with emerging technologies support-
ing patient-management processes. Internet based systems
where patients upload blood glucose results which are
reviewed by health care professionals (HCPs) have been
shown to improve diabetes control over a short term [32].
In this randomised clinical trial, we intend to assess struc-
tured SMBG in this population by comparing no SMBG
monitoring (control), SMBG alone, and SMBG with tel-
ecare. This paper summarises the current approved
protocol in use at 16 participating centres across Wales
and England.
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